A phase I study of paclitaxel in combination with etoposide in patients with stage IIIB/IV non-small cell lung cancer (NSCLC)

Lung Cancer

Volumn 19, Issue 1, 1998, Pages 31-36

  Ukena, Dieter ^a   Berg, Monika ^a   Leutz, Michaela ^a   Zell, Lothar ^a   Schlimmer, Paul ^a   Sybrecht, Gerhard W ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Etoposide; Lung cancer; Non small cell lung cancer; Paclitaxel

Indexed keywords

ETOPOSIDE; PACLITAXEL;

ADENOCARCINOMA; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; HISTOLOGY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MUCOSA INFLAMMATION; MYALGIA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL;

EID: 0031973760     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(97)00071-8     Document Type: Article

References (17)

1. Souquet P.J., Chauvin F., Boissel J.P.et al. Polychemotherapy in advanced non-small cell lung cancer: A meta-analysis. Lancet. 342:1993;19-21.
2. Spencer C.M., Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs. 48:1994;794-847.
3. Chang A.Y., Kim K., Glick J.et al. Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small cell lung cancer: The Eastern Cooperative Oncology Group results. J Natl Cancer Inst. 85:1993;388-394.
4. Murphy W.K., Fossella F.V., Winn R.J.et al. Phase II study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst. 85:1993;384-388.
5. Gatzemeier U., Heckmayer M., Neuhauss R.et al. Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer. 12(Suppl 2):1995;S101-S106.
6. Hainsworth J.D.F., Thompson D.S., Greco F.A. Paclitaxel by 1-hour infusion: an active drug in metastatic non-small cell lung cancer. J Clin Oncol. 13:1995;1609-1614.
7. Stähelin H.F., von Wartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: Ninth Cain Memorial Award Lecture. Cancer Res. 51:1991;5-15.
8. Finkelstein D.M., Ettinger D.S., Ruckdeschel J.C. Long-term survivors in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group study. J Clin Oncol. 4:1986;702-709.
9. Leutz M., Ukena D., Sybrecht G.W. Determination of the maximum tolerated dose (MTD) of paclitaxel (PTX) in combination with etoposide (ETO) in patients with non-small cell lung cancer. Am J Respir Crit Care Med. 153:1996;A317.
10. Eisenhauer E.A., ten Bokkel Huinink W.W., Swenerton K.D.et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol. 12:1994;2654-2666.
11. Belani C.P., Asiner J., Hiponia D., Engstrom C. Paclitaxel and carboplatin with and without filgrastim support in patients with metastatic non-small cell lung cancer. Semin Oncol. 22(Suppl 9):1995;7-12.
12. Rowinsky E.K., Chaudhry V., Forastiere A.A.et al. Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol. 11:1993;2010-2020.
13. Lipton R.B., Apfel S.C., Dutcher J.P.et al. Taxol produces a predominantly sensory neuropathy. Neurology. 39:1989;368-373.
14. Brown T., Havlin K., Weiss G.et al. A phase I trial of taxol given by a 6-hour intravenous infusion. J Clin Oncol. 9:1991;1261-1267.
15. Einzig A.I., Wiernik P.H., Sasloff J.et al. Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol. 10:1992;1748-1753.
16. Schiller J.H., Storer B., Tutsch K.et al. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer. J Clin Oncol. 12:1994;241-248.
17. Langer C.J., Leighton J.C., Comis R.L.et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol. 13:1995;1860-1870.